← All trials
NCT03052842
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 9, 2017
- Primary completion
- Apr 5, 2017
- Completion date
- Apr 5, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- C3J TherapeuticsLead sponsor
- Vantage Data Designs, Inc.Collaborator
- E Squared Trials and Registries, Inc.Collaborator
- Agility Clinical, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.